The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery

The high frequency of RAS mutations in human cancers (33%) has stimulated intense interest in the development of anti-Ras inhibitors for cancer therapy. Currently, the major focus of these efforts is centered on inhibitors of components involved in Ras downstream effector signaling. In particular, m...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Neel, Nicole F., Martin, Timothy D., Stratford, Jeran K., Zand, Tanya P., Reiner, David J., Der, Channing J.
Формат: Artigo
Язык:Inglês
Опубликовано: SAGE Publications 2011
Предметы:
Monographs
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3128631/
https://ncbi.nlm.nih.gov/pubmed/21779498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1947601911407329
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы